These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 27354164)

  • 1. Therapeutic Vaccination against A Modified Minimal Survivin Epitope Induces Functional CD4 T Cells That Recognize Survivin-Expressing Cells.
    Nitschke NJ; Bjoern J; Met O; Svane IM; Andersen MH
    Scand J Immunol; 2016 Sep; 84(3):191-3. PubMed ID: 27354164
    [No Abstract]   [Full Text] [Related]  

  • 2. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.
    Becker JC; Andersen MH; Hofmeister-Müller V; Wobser M; Frey L; Sandig C; Walter S; Singh-Jasuja H; Kämpgen E; Opitz A; Zapatka M; Bröcker EB; Thor Straten P; Schrama D; Ugurel S
    Cancer Immunol Immunother; 2012 Nov; 61(11):2091-103. PubMed ID: 22565484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
    Straetemans T; van Brakel M; van Steenbergen S; Broertjes M; Drexhage J; Hegmans J; Lambrecht BN; Lamers C; van Der Bruggen P; Coulie PG; Debets R
    Clin Dev Immunol; 2012; 2012():586314. PubMed ID: 22400038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
    Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
    J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice.
    Kasamatsu J; Takahashi S; Azuma M; Matsumoto M; Morii-Sakai A; Imamura M; Teshima T; Takahashi A; Hirohashi Y; Torigoe T; Sato N; Seya T
    Immunobiology; 2015 Jan; 220(1):74-82. PubMed ID: 25257859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
    Carreno BM; Magrini V; Becker-Hapak M; Kaabinejadian S; Hundal J; Petti AA; Ly A; Lie WR; Hildebrand WH; Mardis ER; Linette GP
    Science; 2015 May; 348(6236):803-8. PubMed ID: 25837513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.
    Wobser M; Keikavoussi P; Kunzmann V; Weininger M; Andersen MH; Becker JC
    Cancer Immunol Immunother; 2006 Oct; 55(10):1294-8. PubMed ID: 16315030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of secondary anchor amino acid substitutions on the immunogenic properties of an HLA-A*0201-restricted T cell epitope derived from the Trypanosoma cruzi KMP-11 protein.
    Lasso P; Cárdenas C; Guzmán F; Rosas F; Thomas MC; López MC; González JM; Cuéllar A; Campanera JM; Luque FJ; Puerta CJ
    Peptides; 2016 Apr; 78():68-76. PubMed ID: 26854383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
    Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
    Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
    Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
    Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
    Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
    Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes.
    Køllgaard T; Ugurel-Becker S; Idorn M; Andersen MH; Becker JC; Straten PT
    PLoS One; 2015; 10(7):e0131934. PubMed ID: 26176858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
    Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
    J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients.
    Widenmeyer M; Griesemann H; Stevanović S; Feyerabend S; Klein R; Attig S; Hennenlotter J; Wernet D; Kuprash DV; Sazykin AY; Pascolo S; Stenzl A; Gouttefangeas C; Rammensee HG
    Int J Cancer; 2012 Jul; 131(1):140-9. PubMed ID: 21858810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.